# OnCo record gv20-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/gv20-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "gv20-therapeutics" ;
  schema:name "GV20 Therapeutics"@en ;
  schema:alternateName "GV20 Therapeutics"@en ;
  schema:description "GV20 Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the anti-IGSF8 antibody GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer."@en ;
  schema:url <https://onco.cc/companies/gv20-therapeutics/>, <https://gv20tx.com> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://gv20tx.com>, <https://clinicaltrials.gov/search?lead=GV20%20Therapeutics> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/nct05669430/>, <https://onco.cc/trials/nct07070518/> .